DeepMed Research

Leap Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2011-01-01

Employees: 54

Market Cap: $113.2M

Website: http://www.leaptx.com

Clinical Trials

Phase 2 Study of DKN-01 in Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer
Colo-rectal Cancer
Colorectal Cancer Metastatic
Colorectal Adenocarcinoma

Interventions: Drug: DKN-01
Drug: FOLFIRI
Drug: Bevacizumab
Drug: FOLFOX

First Posted Date: 2022-07-29

Last Posted Date: 2025-04-02

Lead Sponsor: Leap Therapeutics, Inc.

Target Recruit Count: 188

Registration Number: NCT05480306

Locations: 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Florida Cancer Specialists & Research Institute (FCS), Cape Coral, Florida, United States

and more 34 locations

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

Conditions: Esophageal Neoplasm
Adenocarcinoma of the Gastroesophageal Junction
GastroEsophageal Cancer
Squamous Cell Carcinoma
Gastric Adenocarcinoma
Endometrial Cancer
Uterine Cancer
Ovarian Cancer
Carcinosarcoma
Gastric Cancer

First Posted Date: 2020-12-23

Last Posted Date: 2025-04-01

Lead Sponsor: Leap Therapeutics, Inc.

Registration Number: NCT04681248

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Cedars Sinai Medical Care Foundation, Los Angeles, California, United States

and more 2 locations

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Phase 2

Active, not recruiting

Conditions: Gastric Adenocarcinoma
Gastric Cancer
GastroEsophageal Cancer

Interventions: Drug: Tislelizumab 200mg
Drug: DKN-01 300mg
Drug: DKN-01 600mg
Drug: DKN-01 400mg
Drug: Capecitabine 1000mg/ m2 BID
Drug: Tislelizumab 400mg
Drug: Oxaliplatin
Drug: Fluorouracil
Drug: Leucovorin Calcium

First Posted Date: 2020-04-27

Last Posted Date: 2024-01-22

Lead Sponsor: Leap Therapeutics, Inc.

Target Recruit Count: 232

Registration Number: NCT04363801

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States

and more 45 locations

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors
Advanced Triple Negative Breast Cancer
Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer
Advanced Metastatic Castration-Resistant Prostate Cancer
Advanced Platinum-Resistant Ovarian Cancer

Interventions: Drug: TRX518
Drug: Cyclophosphamide
Drug: Avelumab

First Posted Date: 2019-03-04

Last Posted Date: 2023-11-30

Lead Sponsor: Leap Therapeutics, Inc.

Target Recruit Count: 10

Registration Number: NCT03861403

Locations: 🇺🇸
Horizon Oncology Research, Lafayette, Indiana, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 1 locations

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

Phase 2

Completed

Conditions: Endometrial Cancer
Uterine Cancer
Ovarian Cancer
Carcinosarcoma

Interventions: Drug: 300mg DKN-01
Drug: Paclitaxel
Drug: 600mg DKN-01

First Posted Date: 2018-01-10

Last Posted Date: 2023-07-12

Lead Sponsor: Leap Therapeutics, Inc.

Target Recruit Count: 111

Registration Number: NCT03395080

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 14 locations

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: TRX518 monotherapy
Drug: TRX518 with pembrolizumab
Drug: TRX518 with nivolumab
Drug: TRX518 with gemcitabine

First Posted Date: 2015-12-11

Last Posted Date: 2020-10-26

Lead Sponsor: Leap Therapeutics, Inc.

Target Recruit Count: 109

Registration Number: NCT02628574

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
University Hospitals, Cleveland, Ohio, United States

and more 3 locations

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Phase 1

Completed

Conditions: Carcinoma of Intrahepatic and Extra-hepatic Biliary System
Carcinoma of Gallbladder
Bile Duct Cancer
Cholangiocarcinoma

Interventions: Drug: DKN-01
Drug: gemcitabine
Drug: cisplatin

First Posted Date: 2015-03-03

Last Posted Date: 2018-09-10

Lead Sponsor: Leap Therapeutics, Inc.

Target Recruit Count: 51

Registration Number: NCT02375880

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

Phase 1

Completed

Conditions: Esophageal Neoplasms
Adenocarcinoma of the Gastroesophageal Junction
Gastroesophageal Cancer
Squamous Cell Carcinoma
Gastric Adenocarcinoma

Interventions: Drug: DKN-01 150 mg
Drug: Paclitaxel
Drug: DKN-01 300 mg
Drug: Pembrolizumab

First Posted Date: 2013-12-17

Last Posted Date: 2023-11-01

Lead Sponsor: Leap Therapeutics, Inc.

Target Recruit Count: 151

Registration Number: NCT02013154

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
CTRC @ The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

and more 7 locations

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: DKN-01 300 mg
Drug: DKN-01 600 mg
Drug: Standard of Care

First Posted Date: 2012-10-22

Last Posted Date: 2017-03-13

Lead Sponsor: Leap Therapeutics, Inc.

Target Recruit Count: 8

Registration Number: NCT01711671

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Phase 1

Completed

Conditions: Multiple Myeloma
Solid Tumors
Non-Small Cell Lung Cancer

Interventions: Drug: DKN-01

First Posted Date: 2011-10-24

Last Posted Date: 2016-09-28

Lead Sponsor: Leap Therapeutics, Inc.

Target Recruit Count: 32

Registration Number: NCT01457417

Locations: 🇺🇸
New York Oncology Hematology, P.C., Albany, New York, United States
🇺🇸
Texas Oncology - Tyler, Tyler, Texas, United States
🇺🇸
Texas Oncology - Baylor, Charles A. Sammonds Cancer Center, Dallas, Texas, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy